The same efficacy was only obtained with an 8-fold dose of PTX (8 mg/kg) or PTX plus P-gp inhibitor XR9576, which showed that targeting the tumor vasculature rather than the resistant tumor cells offered a promising strategy for the treatment of multidrug-resistant cancer. This evidence concerns the gene PGP and neoplasm.